利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

11 条记录 (耗时 0.015 秒)

    STATIN AND OMEGA-3 FATTY ACIDS FOR LIPID THERAPY
    1.
    发明申请
    STATIN AND OMEGA-3 FATTY ACIDS FOR LIPID THERAPY 审中-公开
    脯氨酸和OMEGA-3脂肪酸用于脂质治疗

    公开(公告)号：US20070191467A1

    公开(公告)日：2007-08-16

    申请号：US11742292

    申请日：2007-04-30

    申请人： Roelof Rongen ,  George Bobotas ,  Egil Bodd ,  Hogne Vik

    发明人： Roelof Rongen ,  George Bobotas ,  Egil Bodd ,  Hogne Vik

    IPC分类号： A61K31/401 ,  A61K31/366 ,  A61K31/22 ,  A61K31/202

    CPC分类号： A61K31/366 ,  A61K31/202 ,  A61K31/22 ,  A61K31/232 ,  A61K31/351 ,  A61K31/40 ,  A61K31/401 ,  A61K2300/00

    摘要： A method of lipid therapy, comprising providing a subject group having a baseline triglyceride level of 200 to 499 mg/dl and being at or near its low-density lipoprotein cholesterol (LDL-C) level goal, and reducing the triglyceride level and the non-high-density lipoprotein cholesterol (non-HDL-C) level of the subject group as compared to treatment with a 3-hydroxy-3-methyl glutaryl coenzyme A (HMG CoA) inhibitor alone, by administering to the subject group an effective amount of an HMG CoA inhibitor and a composition comprising omega-3 fatty acids.

    摘要翻译： 一种脂质治疗方法，包括提供具有200至499mg / dl的基线甘油三酯水平并且处于或接近其低密度脂蛋白胆固醇（LDL-C）水平目标的受试者组，并且降低甘油三酯水平和非 - 与单独使用3-羟基-3-甲基戊二酰辅酶A（HMG CoA）抑制剂的治疗相比，本发明组的高密度脂蛋白胆固醇（非HDL-C）水平通过向受试者组施用有效量 的HMG CoA抑制剂和包含ω-3脂肪酸的组合物。

    Omega-3 fatty acids and dyslipidemic agent for lipid therapy
    2.
    发明申请
    Omega-3 fatty acids and dyslipidemic agent for lipid therapy 审中-公开
    欧米加-3脂肪酸和血脂异常剂用于脂质治疗

    公开(公告)号：US20060211762A1

    公开(公告)日：2006-09-21

    申请号：US11284095

    申请日：2005-11-22

    申请人： Roelof Rongen ,  George Bobotas ,  Egil Bodd ,  Hogne Vik

    发明人： Roelof Rongen ,  George Bobotas ,  Egil Bodd ,  Hogne Vik

    IPC分类号： A61K31/401 ,  A61K31/366 ,  A61K31/22 ,  A61K31/202

    CPC分类号： A61K31/202 ,  A61K31/22 ,  A61K31/232 ,  A61K31/351 ,  A61K31/366 ,  A61K31/401 ,  A61K31/426 ,  A61K2300/00

    摘要： A method and composition for blood lipid therapy by administering to the subject an effective amount of a dyslipidemic agent and omega-3 fatty acids. The method utilizes a single administration or a unit dosage of a combination of dyslipidemic agent and omega-3 fatty acids for the treatment of patients with hypertriglyceridemia, hypercholesterolemia, mixed dyslipidemia, coronary heart disease (CHD), vascular disease, artherosclerotic disease and related conditions, and the prevention or reduction of cardiovascular and vascular events.

    摘要翻译： 一种用于血脂治疗的方法和组合物，其通过向受试者施用有效量的血脂异常剂和ω-3脂肪酸。 该方法利用单次给药或单位剂量的血脂异常剂和ω-3脂肪酸的组合来治疗高甘油三酯血症，高胆固醇血症，混合性血脂异常，冠心病（CHD），血管疾病，动脉粥样硬化疾病和相关病症 ，以及预防或减少心血管和血管事件。

    Treatment with omega-3 fatty acids and PPAR agonist and/or antagonist and a combination product thereof
    5.
    发明申请
    Treatment with omega-3 fatty acids and PPAR agonist and/or antagonist and a combination product thereof 审中-公开
    用ω-3脂肪酸和PPAR激动剂和/或拮抗剂及其组合产物治疗

    公开(公告)号：US20060211749A1

    公开(公告)日：2006-09-21

    申请号：US11293513

    申请日：2005-12-05

    申请人： George Bobotas ,  Robert Shalwitz ,  Roelof Rongen

    发明人： George Bobotas ,  Robert Shalwitz ,  Roelof Rongen

    IPC分类号： A61K31/426 ,  A61K31/22 ,  A61K31/202 ,  A61K31/192

    CPC分类号： A61K31/426 ,  A61K31/192 ,  A61K31/202 ,  A61K31/22 ,  A61K45/06 ,  A61K2300/00

    摘要： A method and composition for blood lipid therapy that comprises administering to the subject an effective amount of a PPAR agonist and/or antagonist and an omega-3 fatty acid. The methods and compositions include combination products or concomitant therapy for the treatment of subjects with hypertriglyceridemia, hypercholesteremia, mixed dyslipidemia, vascular disease, artherosclerotic disease and related conditions, obesity, the prevention or reduction of cardiovascular and vascular events, the reduction of insulin resistance, fasting glucose levels and postprandial glucose levels, and/or the reduction of incidence and/or the delay of onset of diabetes.

    摘要翻译： 一种用于血脂治疗的方法和组合物，其包括向受试者施用有效量的PPAR激动剂和/或拮抗剂和ω-3脂肪酸。 所述方法和组合物包括用于治疗患有高甘油三酯血症，高胆固醇血症，混合性血脂异常，血管疾病，动脉粥样硬化疾病和相关病症，肥胖症，预防或减少心血管和血管事件，降低胰岛素抵抗的组合产品或伴随治疗， 空腹血糖水平和餐后葡萄糖水平，和/或糖尿病发病率和/或延迟发作的降低。

    Treatment with omega-3 fatty acids and products thereof
    6.
    发明申请
    Treatment with omega-3 fatty acids and products thereof 审中-公开
    用ω-3脂肪酸及其产品处理

    公开(公告)号：US20070104779A1

    公开(公告)日：2007-05-10

    申请号：US11267581

    申请日：2005-11-07

    申请人： Roelof Rongen ,  Robert Shalwitz

    发明人： Roelof Rongen ,  Robert Shalwitz

    IPC分类号： A61K9/64 ,  A61K31/22 ,  A61K31/202

    CPC分类号： A61K31/22 ,  A61K31/202

    摘要： A method for reducing non-HDL cholesterol levels of a subject comprising administering a pharmaceutical composition comprising omega-3 fatty acids to the subject in an amount sufficient to reduce non-HDL cholesterol. The method may include a reduction of the triglyceride levels of the subject and, optionally, an increase in the HDL cholesterol levels of the subject. These methods can be used concurrently with hypertriglyceridemia therapy prescribed by a doctor.

    摘要翻译： 一种用于降低受试者的非HDL胆固醇水平的方法，其包括以足以降低非HDL胆固醇的量向所述受试者施用包含ω-3脂肪酸的药物组合物。 该方法可以包括减少受试者的甘油三酯水平，以及任选地降低受试者的HDL胆固醇水平。 这些方法可以与医生规定的高甘油三酯血症治疗同时使用。

    Lysozyme gel formulations
    8.
    发明授权
    Lysozyme gel formulations 有权

    公开(公告)号：US09757328B2

    公开(公告)日：2017-09-12

    申请号：US13833773

    申请日：2013-03-15

    申请人： Stefano Ferrari ,  Roelof Rongen

    发明人： Stefano Ferrari ,  Roelof Rongen

    IPC分类号： A61K9/06 ,  A61K9/00 ,  A61K38/47 ,  A61K45/06 ,  A61K47/10

    CPC分类号： A61K9/0014 ,  A61K9/06 ,  A61K38/47 ,  A61K45/06 ,  A61K47/10

    摘要： The present invention relates to formulations of gelled lysozyme achieved by the addition of water to a lysozyme suspension in a solvent, such as an alcohol, with retention of enzymatic activity. It was surprisingly discovered that lysozyme itself is a gelling substance (self-gel) and, therefore, it can be advantageously formulated into topical compositions without the addition of other gelling substances such as cellulose, starch or other polysaccharides. The activity of the lysozyme is enhanced as compared to other formulations of comprising lysozyme. The formulations contained in the present invention are useful in methods in the fields of therapeutics, disinfectants, sanitizers, personal hygiene, and cosmetics for human and veterinary use.

    Treatment of fatty liver
    9.
    发明申请
    Treatment of fatty liver 审中-公开
    脂肪肝的治疗

    公开(公告)号：US20070265340A1

    公开(公告)日：2007-11-15

    申请号：US11649881

    申请日：2007-01-05

    申请人： Robert Shalwitz ,  Roelof Rongen ,  Ihor Terleckyj

    发明人： Robert Shalwitz ,  Roelof Rongen ,  Ihor Terleckyj

    IPC分类号： A61K31/202 ,  A61P1/16

    CPC分类号： A61K31/202

    摘要： Methods and compositions comprising peroxisomal and/or mitochondrial beta oxidation stimulating agents to reverse or resolve, slow the progression of, treat or prevent the development of fatty liver and conditions stemming from fatty liver, such as NASH, liver inflammation, cirrhosis and liver failure. An active agent that by itself is associated with an increased risk of fatty liver development and conditions stemming from fatty liver, such as NASH, liver inflammation, cirrhosis and liver failure, may be administered in combination with peroxisomal and/or mitochondrial beta oxidation stimulating agents. A combination regimen involving such agents, as simultaneous or concomitant therapy, or as a fixed dosage form, is also provided.

    摘要翻译： 包括过氧化物酶体和/或线粒体β氧化刺激剂逆转或解决，缓慢进展，治疗或预防脂肪肝的发展和源于脂肪肝的疾病（例如NASH，肝脏炎症，肝硬化和肝衰竭）的方法和组合物。 与脂肪肝发展风险增加相关的活性成分和脂肪肝（如NASH，肝脏炎症，肝硬化和肝衰竭）引起的病症可能与过氧化物酶体和/或线粒体β氧化刺激剂联合使用 。 还提供了涉及这种药物的联合方案，如同时或伴随治疗，或作为固定剂型。